Endpoints

When it’s used right, social media can be a powerful tool to spread awareness.

Before Tavares Speers was diagnosed with ALS, he already had a big social media following. His tens of thousands of Inst…

After an ALS diagnosis, it can be hard to know where to turn. There are doctors and clinics that offer medical support, and services organizations that can help with getting equipment and things like…

Recently, ALS TDI took an opportunity to reintroduce ourselves. If you follow us on social media, read our emails, or check our website you may have noticed that we have a new way of describing our r…

If you aren’t already, you should be tuning in to I’m Dying to Tell You. It’s a podcast about inspiration, full of compelling interviews with people who have faced incredible challenges – including m…

Biomarkers are an important part of medical research and drug development. A biomarker is a broad term that describes some sort of measurable property of the body, especially one that can tell us som…

The Complement system is an intriguing potential pathway for treating ALS. It’s an essential part of the immune system – and many researchers believe its dysregulation could play a role in some cases…

For years, Lou Gehrig has been recognized as both a face of ALS and a legend of Baseball. But, until now, he did not have an official day dedicated to him by the MLB, unlike some of his fellow legend…

Today on Endpoints, we’re joined by Dr. Leigh Hochberg. He's the the Director of the Center for Neurotechnology and Neurorecovery at Mass General Hospital’s Department of Neurology and a neurologist …

Today we’re joined by Lisa Cross Bonahoom. Lisa is a teacher, singer, actor, director, choreographer, and dancer who was diagnosed with ALS about three years ago. She brings us a story of how this di…

Biomarkers are an important part of medical research and drug development. A biomarker is a broad term that describes some sort of measurable property of the body, especially one that can tell us som…

Finding out a loved one has ALS can be hard enough. But for people whose family members test positive for one of the genetic mutations behind familial ALS, it can bring a whole other set of issues to…

Joe Lynch hosts a podcast called “The Logistics of Logistics.” Normally this show covers topics about the logistics and supply chain industries. But recently Joe decided to switch up the format for o…

10 years ago, today – August 13, 2010 – the doors of the Steve Saling ALS Residence were opened. The residence combines the use of high-tech, accessible automation with specially trained 24/7 caregiv…

AT-1501 is an ALS treatment invented by ALS TDI. In 2018, became the first drug invented by a non-profit biotech to be tested in humans. In November of 2019, it successfully completed a Phase 1 clini…

Today on Endpoints, ALS TDI CEO Dr. Steve Perrin joins us to answer some frequently asked questions about clinical trials: how the process works, and what you can – and can’t – expect when you sign u…

At ALS TDI, our mission is to find effective treatments for ALS. Often that involves trying to invent new drugs of our own, but it can also mean trying to see if treatments developed by others are pr…

When Corey Reich was diagnosed with ALS in 2007, at the age of 21, his family – his sister Clare, and their parents Ted and Wendy – knew they would do whatever they could to support him. Soon after, …

Today we’re joined by David and Scott Lloyd, the brothers behind Racing for ALS. Growing up, David and Scott shared a love of fast cars, but as they got older, began careers, and had families, they k…

 In this episode of the Endpoints Podcast, Dr. Theo Hatzipetros, the Director of Pharmacology at the ALS Therapy Development Institute (ALS TDI) joins us to discuss CMAP and the role it now plays at …

In this episode of the Endpoints, Dr. Steve Perrin, CSO at the ALS Therapy Development Institute, sits down to talk about AMX0035, a drug consisting of a combination of two small molecule compounds: …